CTSB and acute myeloid leukemia: The multivariate adjustment for the above significant clinicopathological features showed that the expression level of CTSB was an independent prognostic factor for both OS (Hazard ratio [HR] =0.393, 95% confidence interval [CI], 0.192-0.805, p=0.011) and DFS (Hazard ratio [HR] =0.363, 95% confidence interval [CI], 0.182-0.725, p=0.004) of AML patients.